These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 15217711)

  • 1. European Working Group (EWG) meeting on myeloproliferative disorders (MPDDs).
    Brière J
    Pathol Biol (Paris); 2004 Jun; 52(5):265-6. PubMed ID: 15217711
    [No Abstract]   [Full Text] [Related]  

  • 2. Introduction to a review series on myeloproliferative neoplasms.
    Cazzola M
    Blood; 2017 Feb; 129(6):659. PubMed ID: 28028028
    [No Abstract]   [Full Text] [Related]  

  • 3. Inclusion of secondary chronic myelomonocytic leukemia and myeloproliferative disease, unclassifiable, in classification of pediatric myeloproliferative disorders.
    Occhipinti E; Correa H; Yu L; Craver R
    J Pediatr Hematol Oncol; 2006 Oct; 28(10):700-1. PubMed ID: 17023836
    [No Abstract]   [Full Text] [Related]  

  • 4. [Recommendations for the cytogenetic management of myeloproliferative syndromes proposed by the French Group for Cytogenetic Hematology].
    Groupe Français de Cytogénétique Hématologique (GFCH)
    Pathol Biol (Paris); 2004 Jun; 52(5):241-4. PubMed ID: 15217703
    [No Abstract]   [Full Text] [Related]  

  • 5. The WHO 2008 classification of Ph-myeloproliferative disorders: statement of the Czech MPD Working Group.
    Schwarz J; Penka M; Indrák K; Pospísilová D; Pytlík R; Dulícek P; Doubek M; Kren L; Campr V;
    Leukemia; 2008 Nov; 22(11):2118-9. PubMed ID: 18418405
    [No Abstract]   [Full Text] [Related]  

  • 6. Topics in pediatric leukemia--myelodysplastic and myeloproliferative disorders of childhood.
    Lasky J; Sakamoto KM
    MedGenMed; 2005 Mar; 7(1):21. PubMed ID: 16369326
    [No Abstract]   [Full Text] [Related]  

  • 7. [Summary of recommendations for the diagnosis and therapy of BCR/ABL-negative myeloproliferation of the Czech Working Group for Ph-negative myeloproliferative disease (CZEMP) of the Czech Hematologic Society CLS JEP ].
    Penka M; Schwarz J; Campr V; Pospíšilová D; Křen L; Nováková L; Bodzásová C; Brychtová Y; Cerná O; Dulíček P; Jonášová A; Kissová J; Kořístek Z; Schützová M; Vonke I; Walterová L;
    Vnitr Lek; 2012 Feb; 58(2):163-8. PubMed ID: 22463098
    [No Abstract]   [Full Text] [Related]  

  • 8. Special edition myeloproliferative neoplasia - disease pathogenesis and treatment options.
    Wolf D; Rumpold H
    Curr Cancer Drug Targets; 2011 Jan; 11(1):1-2. PubMed ID: 21288201
    [No Abstract]   [Full Text] [Related]  

  • 9. [Classification for myeloproliferative neoplasms and function of novel mutations].
    Kirito K
    Rinsho Ketsueki; 2011 Oct; 52(10):1575-84. PubMed ID: 21971234
    [No Abstract]   [Full Text] [Related]  

  • 10. Introduction: myeloproliferative disorders.
    Doll DC; Gabrail NY; List AF
    Semin Oncol; 1995 Aug; 22(4):305-6. PubMed ID: 7638628
    [No Abstract]   [Full Text] [Related]  

  • 11. Recent advances in biological and therapeutic aspects of myeloproliferative disorders.
    Mancini M; Diverio D; Alimena G; Mandelli F
    Curr Opin Hematol; 1994 Jul; 1(4):261-7. PubMed ID: 9371292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Chronic myeloproliferative disorders: from molecular physiopathology to clinical presentation].
    Dan K
    Nihon Naika Gakkai Zasshi; 2007 Jul; 96(7):1329-30. PubMed ID: 17682416
    [No Abstract]   [Full Text] [Related]  

  • 13. [Diagnosis and treatment of BCR/ABL-negative myeloproliferative diseases].
    Hrubisko M
    Vnitr Lek; 2011 Feb; 57(2):138-9. PubMed ID: 21416852
    [No Abstract]   [Full Text] [Related]  

  • 14. Hereditary myeloproliferative disorders.
    Skoda RC
    Haematologica; 2010 Jan; 95(1):6-8. PubMed ID: 20065077
    [No Abstract]   [Full Text] [Related]  

  • 15. Do current response criteria in classical Ph-negative myeloproliferative neoplasms capture benefit for patients?
    Barosi G; Tefferi A; Barbui T;
    Leukemia; 2012 May; 26(5):1148-9. PubMed ID: 22105597
    [No Abstract]   [Full Text] [Related]  

  • 16. The myelodysplastic syndromes and myeloproliferative disorders.
    Williams JL
    Clin Lab Sci; 2004; 17(4):223-34. PubMed ID: 15559729
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The mosaic of myeloid neoplasia: implications for classification.
    Steensma DP
    Leuk Lymphoma; 2008 Jul; 49(7):1228-9. PubMed ID: 18604710
    [No Abstract]   [Full Text] [Related]  

  • 18. Chronic myeloproliferative disorders: the role of tyrosine kinases in pathogenesis, diagnosis and therapy.
    Macdonald D; Cross NC
    Pathobiology; 2007; 74(2):81-8. PubMed ID: 17587879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The myeloproliferative disorders.
    Campbell PJ; Green AR
    N Engl J Med; 2006 Dec; 355(23):2452-66. PubMed ID: 17151367
    [No Abstract]   [Full Text] [Related]  

  • 20. [JAK2 mutation in myeloproliferative disorders].
    Inokuchi K
    Rinsho Ketsueki; 2006 Aug; 47(8):693-700. PubMed ID: 16986707
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.